NCT05143970 2024-03-20
CHANCES
Institut Paoli-Calmettes
Phase 1 Unknown
Clinical Trials
51 trialsNCT04197687 2023-12-18
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
Academic and Community Cancer Research United
Phase 2 Unknown
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT05912062 2023-09-29
BiOnHER
Institut Català d'Oncologia
Unknown
NCT02679040 2023-07-03
HIST-RIC
Institut Paoli-Calmettes
Phase 2 Unknown
NCT00431704 2023-03-24
VinCaT
National Cancer Institute, Naples
Phase 2 Unknown
NCT03412643 2023-03-06
FB-12
NSABP Foundation Inc
Phase 2 Unknown
NCT05656079 2022-12-19
easy laugh
Shanghai Pudong Hospital
Phase NA Unknown
NCT03863223 2022-11-23
A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT03907800 2022-10-27
NeoPATH
Ruijin Hospital
Phase 2 Unknown
NCT05577923 2022-10-13
Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)
Fudan University
Phase 2 Unknown
NCT04917900 2022-10-10
Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer
West China Hospital
Phase 2 Unknown
NCT05483439 2022-08-05
A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer
Shengjing Hospital
Phase 2 Unknown
NCT03913234 2022-05-10
Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients
Yonsei University
Phase 1/2 Unknown
NCT04334330 2022-05-02
Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China
Sun Yat-sen University
Phase 2 Unknown
NCT05346861 2022-04-26
Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab
Fudan University
Phase 3 Unknown
NCT05030519 2022-03-02
A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer
Zhejiang Cancer Hospital
Unknown
NCT03521245 2021-09-14
Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer
OmicsWay Corp.
Unknown
NCT04962425 2021-07-15
Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients
Peking University Third Hospital
Unknown
NCT04961307 2021-07-14
Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab
Peking University Third Hospital
Unknown
NCT04683445 2020-12-24
Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Unknown
NCT04609540 2020-12-16
Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC
Shandong Cancer Hospital and Institute
Unknown
NCT04639271 2020-11-20
Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis
Shandong Cancer Hospital and Institute
Phase 2 Unknown
NCT03367676 2020-03-10
SOBER
Ruijin Hospital
Phase 2 Unknown
NCT04246502 2020-02-05
Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer
Shandong Cancer Hospital and Institute
Phase 2 Unknown
NCT03994107 2020-01-22
Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer
Peking Union Medical College
Phase 1/2 Unknown
NCT04152057 2019-11-05
Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer
West China Hospital
Phase 1/2 Unknown
NCT03756064 2019-08-13
Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer
Zhejiang Cancer Hospital
Phase NA Unknown
NCT03910712 2019-04-10
Pyrotinib
Peking Union Medical College Hospital
Phase 2 Unknown
NCT02689921 2018-09-28
NEOADAPT
Midwestern Regional Medical Center
Phase 2 Unknown
NCT01104571 2018-09-17
EPHOS-B
Institute of Cancer Research, United Kingdom
Phase 3 Unknown
NCT02214004 2018-02-15
HERAKLES
Gangnam Severance Hospital
Phase 2 Unknown
NCT03273595 2017-09-06
Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer
Xijing Hospital
Phase 2 Unknown
NCT03085368 2017-07-28
A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin
Peking Union Medical College Hospital
Phase 2/3 Unknown
NCT03006614 2017-01-16
PERS
Sun Yat-sen University
Phase 3 Unknown
NCT01304797 2017-01-06
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
Merrimack Pharmaceuticals
Phase 1 Unknown
NCT02656589 2016-10-13
microRNA of Human Epidermal Growth Factor Receptor 2 （HER2）Positive Patient Treated With Herceptin
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Unknown
NCT02030561 2016-06-22
NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer
National University Hospital, Singapore
Phase 1/2 Unknown
NCT02510781 2015-07-29
A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs
Hospital Affiliated to Military Medical Science, Beijing
Phase 2 Unknown
NCT02059876 2014-02-12
Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer
Guangdong Provincial People's Hospital
Phase 2 Unknown
NCT00533936 2013-08-26
Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00629278 2013-08-07
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT01625429 2012-11-09
Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer
Shanghai Cancer Hospital, China
Phase 2 Unknown
NCT01428414 2012-08-23
Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer
Fudan University
Phase 2 Unknown
NCT00712140 2011-09-02
Trastuzumab in Treating Women With HER2-Positive Early Breast Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00398489 2010-11-09
Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01170143 2010-07-27
PCH
Fudan University
Phase 2 Unknown
NCT00518583 2010-01-15
Phase II Study in Patients With Operable Breast Cancer
Aptium Oncology Research Network
Phase 2 Unknown
NCT00842998 2009-06-26
HERLAP
Azienda Ospedaliera Ordine Mauriziano di Torino
Phase 2 Unknown
NCT00430001 2008-05-09
Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer
Danish Breast Cancer Cooperative Group
Phase 3 Unknown